

Cancer Epidemiology, Biomarkers & Prevention



Cancer Survivors: A Booming Population

Carla Parry, Erin E. Kent, Angela B. Mariotto, et al.

Cancer Epidemiol Biomarkers Prev 2011;20:1996-2005. Published online October 5, 2011.

Updated Version Access the most recent version of this article at:
doi:[10.1158/1055-9965.EPI-11-0729](https://doi.org/10.1158/1055-9965.EPI-11-0729)

Cited Articles This article cites 25 articles, 9 of which you can access for free at:
<http://cebp.aacrjournals.org/content/20/10/1996.full.html#ref-list-1>

Citing Articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
<http://cebp.aacrjournals.org/content/20/10/1996.full.html#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.

Cancer Survivors: A Booming Population

Carla Parry¹, Erin E. Kent^{1,2}, Angela B. Mariotto³, Catherine M. Alfano¹, and Julia H. Rowland¹

Abstract

Background: In this first article of what is planned to be an annual series, we examine the history of cancer prevalence reporting and the role that these annual figures play in guiding the direction of cancer control research, and specifically the science of cancer survivorship. For this inaugural year, we focus on the confluence of the growing number of survivors and population aging, and the impact these combined trends will have on cancer survivorship in the future.

Methods: State or metro area-level cancer incidence and prevalence data were collected from 9 registries via the Surveillance, Epidemiology, and End Results Program. The complete prevalence method was used to estimate prevalence for 2008 and the Prevalence, Incidence Approach Model method was used to project prevalence data through 2020, assuming flat cancer incidence and survival trends but dynamic U.S. population projections.

Results: As of January 2008, the number of cancer survivors is estimated at 11.9 million. Approximately 60% of cancer survivors are age 65 or older, and by the year 2020, it is estimated that 63% of cancer survivors will be age 65 or older.

Conclusions: Improved survival and population aging converge to generate a booming population of older adult cancer survivors, many of whom have multiple complex health conditions and unique survivorship needs. This demographic shift has important implications for future health care needs and costs of the U.S. population.

Impact: The findings provide information critical for guiding cancer prevention and control research and service provision. *Cancer Epidemiol Biomarkers Prev*; 20(10); 1996–2005. ©2011 AACR.

Introduction

In this first article of what is planned to be an annual series, we examine the history of U.S. cancer prevalence reporting, and the role that these annual figures can play in guiding the direction of cancer control research more broadly, and the science of survivorship specifically. In each of these annual summaries, we will select a special topic of focus. For this inaugural year, the special emphasis for our analysis is on the confluence of the growing number of survivors, and the impact that the aging of our population will have on cancer survivorship in the future.

History of cancer prevalence

For the past 38 years, the nation has looked to the National Cancer Institute (NCI), or more specifically to the NCI supported Surveillance Epidemiology, and End

Results (SEER) tumor registry program, to provide information regarding the success of collective efforts to reduce the national burden of cancer. Launched in 1973 as part of President Nixon's 1971 National Cancer Act, the SEER program began collecting data on cancer cases in the states of Connecticut, Hawaii, Iowa, New Mexico and Utah, and from 2 large metropolitan regions, Detroit and San Francisco, Oakland. Today, the program includes data from all of the original sites along with those from Atlanta, Alaska, Arizona, all of California, rural Georgia, Kentucky, Louisiana, New Jersey, Seattle-Puget Sound that combined, represent approximately 28% of the U.S. population. For greater detail about the SEER program, please refer to the following brochure (1).

The SEER program is widely known for releasing annual cancer incidence and mortality statistics, updated each April. In addition, SEER also provides estimates of cancer prevalence, or the number of individuals alive at a given point in time with a history, or prior diagnosis, of cancer. These estimates include people recently diagnosed with cancer, those living with advancing illness, and long-term survivors. Although the most up-to-date estimates of incidence and mortality can be calculated using cross-sectional data, to generate prevalence figures it is necessary to capture all prior diagnoses and to know the most recent vital status for each of these individuals. Acquisition of this information is challenging for

Authors' Affiliations: ¹Office of Cancer Survivorship; ²Cancer Prevention Fellowship Program; and ³Surveillance Research Program, National Cancer Institute, Bethesda, Maryland

Corresponding Author: Julia H. Rowland, National Cancer Institute/NIH, Office of Cancer Survivorship, Division of Cancer Control and Population Sciences, 6116 Executive Boulevard, Suite 404, Bethesda, MD 20892. Phone: 301-402-2746; Fax: 301-594-5070; E-mail: rowlandj@mail.nih.gov

doi: 10.1158/1055-9965.EPI-11-0729

©2011 American Association for Cancer Research.

population-based cancer registries, for 2 reasons. The first is that not all registries have been collecting cancer diagnosis data long enough to capture all prior cancer diagnoses and include long-term survivors. Hence, estimates using case data from these sources could only be used to provide limited duration prevalence. The second challenge is that most cancer registries are primarily mandated to collect incidence data, and so principally collect information at diagnosis. Follow-up data collection procedures to capture vital status require additional effort. Passive follow-up techniques include linkages to state and federal mortality data, local administrative sources such as voting records, federal systems like social security death claims or Centers for Medicare and Medicaid Services, and other sources. When information is unavailable from these linkages, some registries engage in active follow-up, making an effort to contact survivors, next of kin, physicians, or other cancer registry reporting sources to acquire information about whether these individuals are still alive or have since died. Few people realize that for many years, complete prevalence was actually generated from one registry only: Connecticut. The reason for this is that the Connecticut tumor registry has the longest continuous U.S. history, having been in existence since 1935 with electronic data available since 1950. Most of the other SEER registries were established in the 1970s and later; thus, information on survival available from these sites was based on shorter follow-up times and could not capture longer-term survivors (or those diagnosed before the 1970s).

With the establishment of NCI's Office of Cancer Survivorship (OCS) in 1996, growing attention has been paid


to the lives and care of those living years after cancer treatment. In an effort to better describe this growing population, members of OCS worked with colleagues in NCI's SEER program to promote the development of statistical models that would permit use of the full set of SEER registry cases to estimate national cancer prevalence (2–5). The first figures using this larger data set to project complete prevalence were released in 2002 (6). Data for the most recent prevalence figures from 2008, and methods used to generate these annually, are provided in detail below.

Why focus on aging?

Age is the single most important risk factor for developing cancer (7). This effect is well illustrated in Figure 1 (8). For the majority of the most common cancers, more than half of cases occur in individuals who are 65 year or older at the time of diagnosis: for example, 68.5% of lung cancer, 66.8% of colon cancer, and 59.6% of prostate cancer cases occur in older adults. Exceptions to this pattern are breast cancer and ovarian cancer, in which the majority of cases occur in individuals under the age of 65 years.

The aging of the baby boomer generation (those born between 1946 and 1964), the first wave of whom started turning 65 on January 1, 2011, promises to expand our survivor population and to elevate the importance of understanding and addressing the needs of older cancer survivors. In 2008, an estimated 39 million U.S. citizens (13%) were 65 years or older (9). By the year 2030, this proportion is projected to increase to 19.3% (10, 11). Moreover, the segment of the population 85 and older

Figure 1. Proportion of tumors in patients age 65 and older at diagnosis (7).



(the "oldest old") is expected to more than triple in size between 2008 and 2050: from 5.7 million to 19 million people (11). These trends have sobering implications for health care delivery for 2 reasons: the imminent volume of demand, and the complexity and costs associated with treating the concurrent health burden associated with the prevalence of chronic illness and cancer in older adults.

Older adult cancer survivors may evidence psychosocial adaptation comparable with their age-matched peers and often show greater resilience than younger cancer survivors (12, 13). However, they may also experience greater illness burden, in part because of concurrence of comorbid conditions and cancer. A cancer diagnosis is likely to coexist with other chronic conditions in the older adult population, as 80% of older adults have at least 1 chronic health condition and 50% have at least 2 chronic conditions (9). The most common chronic conditions in older adults include hypertension, arthritis, cancer, and diabetes (10). In addition, approximately 27% of adults aged 60 or older are obese, and 38% report having a disability (10). This morbidity profile is reflected in medical costs: the costs associated with cancer care totaled 124.57 billion U.S. dollars in 2010 (14), and the treatment and management of chronic illness accounts for roughly 95% of health care expenditures in older adults (15).

In addition to their independent effects on health outcomes and health care costs, cancer and chronic illness may interact to adversely affect health and psychosocial outcomes in older adult cancer survivors. Coexisting cancer and chronic conditions may limit the intensity and duration of cancer treatment (16–19), be related to poorer survival (20), and put survivors at higher risk for exacerbation of comorbid conditions or declines in physical functioning posttreatment (16, 21, 22). These outcomes may render survivors in greater need of support services, and/or generate concerns about loss of independence (23). Although not yet well understood, the interaction of cancer and chronic illness is an increasingly important area that will shape cancer survivorship and service delivery in years to come, especially among the older adult population.

Finally, increased survival and older age are accompanied by greater risk for developing subsequent cancers. SEER registry data from 1975 to 2001 indicate that nearly 8% of the current cancer survivor population has a history of more than 1 cancer (24). Further, findings from this report revealed that roughly 16% of newly diagnosed cancer cases occur in individuals with a prior cancer history and the prevalence of multiple cancers increases with age. Whereas multiple cancers by age group are less than 1% for survivors aged 19 and younger, the prevalence data show an upward trend across the life course: 2.6% (ages 20–49), 4.7% (ages 50–59), 7% (ages 60–69), 10% (ages 70–79), and 12.1% for survivors aged 80 and older (16). For these compelling reasons, attention in this report of the 2008 annual prevalence figures is given to the impact of aging on survivorship trends.


Materials and Methods

To estimate U.S. complete prevalence, that is, the number of people in the United States ever diagnosed with cancer that were alive on January 1, 2008, the latest incidence and follow-up data on individuals diagnosed with malignant cancer between 1975 and 2007 were obtained from the 9 SEER registries that have the longest follow-up periods and cover approximately 10% of the U.S. population: Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco, Oakland, Seattle-Puget Sound, and Utah.

U.S. complete prevalence is estimated through a 3-step method. In this method, we first calculated 33-year limited duration cancer prevalence by counting the number of individuals diagnosed during 1975 and 2007 alive at January 1, 2008 in the SEER-9 areas. This method includes adjustment for cancer patients lost to follow-up. To include long-term survivors, people diagnosed with cancer prior to 1975 and still alive at January 1, 2008, the Complete Prevalence (COMPREV) method was used. This method fits parametric models to incidence and survival data from the SEER registry and extrapolates into the past to estimate the proportion of survivors alive who had been diagnosed prior to the first diagnosis date in the dataset (January 1, 1975). Finally, we applied these estimates to the entire U.S. population, while controlling for age, sex, and race. Population size was based on an average of the 2007 and 2008 U.S. population data. The final figures represent U.S. complete prevalence estimates, or the number of people ever diagnosed with cancer and alive on January 1, 2008 regardless of how long ago the diagnosis was made, characterized by current age, sex, time since diagnosis, and cancer site.

This 3-step approach for the estimation of U.S. cancer prevalence is the chosen method for the reporting and monitoring of cancer prevalence because it uses fewer assumptions than methods that project prevalence into the future and more closely approximates the observed data. A different method is used for cancer prevalence projections. The Prevalence, Incidence Approach MODEL (PIAMOD; ref. 25) method projects prevalence by fitting models to cancer incidence, cancer survival, and mortality for other causes of death data. In a recent publication (14), this method was used to provide projections of cancer prevalence through 2020. These prevalence projections include nonmalignant tumors, with the exception of nonmalignant cervical cancer and benign brain cancer. Because the PIAMOD method fits models to incidence and survival data it provides prevalence estimates and projections that incorporate past observed trends but also allow for projections using various assumptions about future incidence and survival trends. In this article, we present prevalence projections from 2010 through 2020. These projections use dynamic U.S. population projections from the U.S. Census Bureau and are based on the assumption that future cancer incidence and survival trends remained the same as observed in the last years

Figure 2. Estimated number of cancer survivors in the United States from 1971 to 2008 (23).



of data collection. For more details on the methods please refer to Mariotto and colleagues (11).

Results

Figure 2 shows the estimated number of cancer survivors in the United States between the years 1971 and 2008 (26). Graphically illustrated in this figure is the steady upward trend in the number of those living with a cancer history, culminating in an estimated 11.9 million cancer survivors as of January 1, 2008. Since 1971, when the "war on cancer" was launched, there has been an almost 4-fold increase in the number of survivors. This increase is a testament to the many advances in cancer detection, treatment, and supportive care in the intervening decades.

Of these 11.9 million men and women, the majority were diagnosed more than 5 years ago. Impressively, approximately 15% were diagnosed more than 20 years ago (Fig. 3; ref. 26).

The most common diagnoses among cancer survivors include female breast cancer (22%), prostate cancer (20%), and colorectal cancer (9%), followed by gynecologic (8%) and hematologic (8%) cancers. The most common tumor

sites for women (all ages) included breast (41%), corpus or uterus (9%), and colorectal (9%) cancer. The most common tumor sites for men (all ages) included prostate (43%), colorectal (10%), and hematologic (10%) cancers. It is important to note that despite being the most commonly diagnosed cancer for both sexes, lung cancer represents only 3% of the prevalent population, a reminder that this disease remains a continuing challenge for cancer control science. The distribution of cancer prevalence by age, gender, and type of cancer is provided in Table 1.

Approximately 60% of cancer survivors alive in the United States in 2008 were older adults, aged 65 or older (see Fig. 4); 13% were aged 65 to 69, 25% were aged 70 to 79, and 22% were aged 80 or older. The most common cancer sites diagnosed in older adults are lung, prostate, and breast cancer (7). Those diagnosed between birth and age 49 represent only 13% of the prevalent population; individuals aged 50 to 64 account for another 27%.

Figure 5 shows the projected number of those 65 years and older with a history of cancer (including nonmalignant cancers with the exception of nonmalignant cervix cancer and benign brain cancer) from 2010 through 2020 (26). The projections presented above suggest these numbers may reach an estimated 11 million survivors aged 65

Figure 3. Estimated number of persons alive in the U.S. diagnosed with cancer on January 1, 2008 by time from diagnosis and gender (invasive/1st primary cases only, $n = 11.9$ M survivors; ref. 23).




Table 1. Complete prevalence counts by age, gender, and site at January 1, 2008 (invasive/1st primary cases only, n = 11.9 M survivors; ref. 7)

	All ages	0	01-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	
All sites	11,957,599	551	9,318	22,368	28,970	44,593	62,341	93,812	131,136	225,922	359,045	584,708	836,118	1,111,214	1,380,866	1,474,430	1,485,581	1,516,005	1,338,787	1,251,835	
Male and female																					
Male	5,505,862	248	5,010	12,112	15,633	23,970	32,541	44,037	56,446	88,190	131,499	206,615	311,340	460,062	631,790	730,212	777,949	796,277	663,612	518,319	
Female	6,451,737	303	4,308	10,256	13,337	20,623	29,800	49,775	74,690	137,732	227,547	378,093	524,777	651,152	749,075	744,217	707,632	719,728	675,175	733,515	
Brain and other nervous system																					
Male and female	128,193	72	1,388	4,343	6,036	7,686	8,572	8,959	8,218	10,991	12,869	14,077	11,880	11,064	8,075	5,480	3,701	2,395	1,560	827	
Male	67,624	11	772	2,321	3,252	4,397	4,746	4,821	4,475	5,967	6,668	7,390	6,000	6,010	4,141	2,740	1,785	1,203	690	233	
Female	60,569	61	617	2,022	2,784	3,289	3,826	4,138	3,743	5,024	6,201	6,687	5,880	5,053	3,933	2,739	1,917	1,192	870	595	
Breast																					
Male and female	2,645,621	0	0	0	11	73	352	1,990	7,988	26,728	67,393	140,336	221,020	288,454	348,039	344,867	312,004	308,126	283,357	294,882	
Male	13,616	0	0	0	0	11	5	38	43	167	409	699	1,241	1,770	1,852	2,113	1,859	1,695	1,695	1,713	
Female	2,632,005	0	0	0	11	73	341	1,985	7,951	26,684	67,227	139,927	220,321	287,213	346,269	343,014	309,891	306,267	281,662	293,169	
Cervix uteri																					
Male and female	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Male	243,884	0	0	0	22	34	358	1,652	4,918	11,861	17,666	24,965	27,704	30,230	26,983	23,530	22,227	20,093	16,460	15,181	
Colon and rectum																					
Male and female	1,110,077	0	11	0	34	91	614	1,733	3,017	7,041	15,578	30,176	54,056	80,604	101,876	124,487	145,889	168,290	173,033	203,547	
Male	542,127	0	11	0	23	245	813	1,441	3,760	8,034	15,879	28,831	44,053	56,079	68,392	77,026	84,123	80,000	80,000	73,416	
Female	567,950	0	0	0	34	68	369	921	1,576	3,282	7,544	14,297	25,225	36,551	45,797	56,094	68,862	84,166	93,033	130,131	
Corpus and uterus, NOS																					
Male and female	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Male	573,300	0	0	0	0	54	91	308	1,338	3,853	7,761	15,689	29,976	49,658	67,406	71,394	70,507	74,094	78,376	102,795	
Esophagus																					
Male and female	30,204	0	0	0	0	0	0	14	32	146	467	1,035	2,008	3,201	4,711	4,850	4,425	4,544	3,041	1,730	
Male	23,026	0	0	0	0	0	0	14	21	107	378	835	1,633	2,645	3,825	3,918	3,315	3,254	2,027	1,053	
Female	7,178	0	0	0	0	0	0	0	11	38	89	201	375	556	886	932	1,111	1,290	1,014	677	
Hodgkin lymphoma																					
Male and female	166,776	0	11	280	797	2,958	6,687	11,607	13,531	18,460	21,717	23,373	19,243	16,803	11,606	7,385	4,970	3,520	2,197	1,630	
Male	86,218	0	11	181	534	1,647	3,180	5,546	6,816	9,142	10,833	12,128	10,100	8,984	6,616	4,304	2,748	1,731	984	734	
Female	80,558	0	0	99	264	1,311	3,508	6,061	6,715	9,318	10,884	11,245	9,143	7,819	4,990	3,081	2,222	1,788	1,212	896	
Kidney and renal pelvis																					
Male and female	295,074	22	635	2,094	2,295	2,677	2,472	2,552	3,155	5,439	9,796	16,612	23,576	31,721	37,772	38,662	35,879	34,147	25,852	20,715	
Male	174,350	11	356	1,045	1,056	1,312	1,227	1,213	1,484	2,909	5,607	9,673	14,916	19,856	23,740	24,493	21,620	20,130	14,225	9,479	
Female	121,724	11	279	1,048	1,239	1,365	1,245	1,339	1,671	2,530	4,190	6,939	8,659	11,865	14,032	14,169	14,259	14,018	11,627	11,237	
Larynx																					
Male and female	88,941	0	0	0	0	0	34	52	116	220	811	2,616	5,103	8,126	11,182	13,403	14,464	14,141	10,624	8,052	
Male	71,273	0	0	0	0	0	34	10	85	111	497	1,888	3,786	6,387	9,221	10,844	11,364	11,474	8,965	6,606	

(Continued on the following page)

Table 1. Complete prevalence counts by age, gender, and site at January 1, 2008 (invasive/1st primary cases only, $n = 11.9$ M survivors; ref. 7) (Cont'd)

	All ages	0	01-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
Leukemia	17,668	0	0	0	0	0	41	31	109	314	728	1,317	1,739	1,960	2,559	3,099	2,667	1,658	1,446	
Male and female	253,350	55	2,923	8,347	9,981	11,893	10,796	9,829	8,825	9,063	8,864	11,847	14,367	17,920	21,635	23,020	23,136	22,941	19,906	18,001
Male	142,702	16	1,537	4,670	5,468	6,508	5,760	5,126	4,455	5,259	5,066	6,827	8,569	10,710	13,387	13,846	14,108	12,905	10,459	8,025
Female	110,648	39	1,386	3,676	4,513	5,385	4,702	4,370	3,804	3,798	3,798	5,021	5,798	7,210	8,248	9,174	9,028	10,037	9,447	9,976
Acute lymphocytic leukemia	62,193	27	2,317	7,198	8,656	10,027	8,411	7,127	5,359	4,676	2,857	1,865	1,028	812	673	489	212	195	161	102
Male and female	34,306	5	1,170	4,008	4,735	5,695	4,478	3,902	2,733	2,768	1,749	942	674	431	363	280	121	121	109	23
Male	27,887	22	1,147	3,190	3,922	4,332	3,933	3,225	2,626	1,908	1,109	923	354	382	310	210	91	74	51	80
Liver and intrahepatic bile duct	31,175	11	404	438	472	467	404	378	250	538	710	1,665	3,510	5,959	4,596	3,457	2,855	2,569	1,542	950
Male and female	21,567	0	268	144	242	295	208	206	187	239	449	1,184	2,723	4,716	3,555	2,336	1,941	1,551	896	426
Male	9,608	11	136	294	230	172	196	172	63	298	261	481	788	1,242	1,042	1,121	914	1,018	646	523
Lung and bronchus	373,489	0	22	44	51	50	349	411	844	1,630	3,503	10,223	19,365	29,692	47,410	59,303	61,874	62,134	47,184	29,400
Male and female	173,428	0	22	22	39	30	178	199	388	731	1,642	4,180	8,675	14,922	22,709	28,599	28,967	28,876	21,038	12,209
Male	200,061	0	0	22	11	19	170	212	456	899	1,861	6,043	10,690	14,770	24,700	30,704	32,907	33,258	26,147	17,192
Melanoma of the skin	822,770	0	0	164	342	1,408	4,309	11,127	18,213	30,583	45,632	70,860	87,467	99,405	104,604	87,864	76,170	74,183	59,568	50,871
Male and female	400,706	0	0	92	113	588	1,536	3,334	6,138	10,458	17,152	29,113	39,136	48,396	54,868	47,961	43,596	41,917	31,361	24,945
Male	422,064	0	0	71	229	820	2,773	7,793	12,075	20,125	28,480	41,747	48,331	51,009	49,735	39,903	32,574	32,266	28,208	25,926
Myeloma	64,615	0	0	0	5	0	28	64	160	576	1,475	2,751	4,973	7,578	9,703	9,731	8,673	7,892	6,356	4,649
Male and female	35,445	0	0	0	5	0	17	43	121	405	855	1,517	2,807	4,386	5,751	5,393	4,823	4,239	3,247	1,838
Male	29,170	0	0	0	0	0	11	21	39	171	621	1,235	2,166	3,192	3,952	4,338	3,850	3,653	3,109	2,811
NonHodgkin lymphoma	454,378	0	181	950	1,534	3,520	4,577	6,079	7,695	12,120	19,263	27,027	38,174	46,471	52,688	54,130	49,695	51,621	42,207	36,444
Male and female	235,433	0	126	598	1,025	2,303	3,028	3,794	4,579	7,324	11,188	16,115	21,573	24,991	28,391	28,744	24,925	24,689	18,088	13,955
Male	218,945	0	55	352	508	1,218	1,549	2,286	3,117	4,797	8,075	10,913	16,601	21,481	24,297	25,387	24,770	26,932	24,119	22,489
Oral cavity and pharynx	253,165	0	44	136	202	736	1,142	1,626	2,692	4,301	7,314	15,173	24,247	31,521	34,206	31,861	28,601	25,946	22,868	20,549
Male and female	164,159	0	11	44	110	323	677	786	1,216	2,105	4,285	10,101	16,694	22,517	23,994	21,883	18,676	16,384	13,473	10,880
Male	89,006	0	33	93	143	465	840	1,476	2,196	3,029	5,072	7,553	9,004	10,212	9,978	9,926	9,926	9,561	9,394	9,669
Ovary	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Male and female	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Male	177,578	0	11	72	259	604	1,462	1,996	2,237	4,346	7,021	12,429	17,716	20,943	22,546	19,771	19,141	18,086	14,993	13,945
Pancreas	34,657	0	0	0	6	63	108	87	205	529	753	1,859	2,801	3,813	4,716	4,593	4,597	4,515	3,240	2,773
Male and female	16,811	0	0	0	11	57	22	82	238	325	999	1,441	2,069	2,531	2,564	2,564	2,280	2,068	1,284	842
Male	17,846	0	0	0	6	52	51	66	122	291	428	860	1,359	1,744	2,186	2,029	2,318	2,447	1,956	1,930
Prostate	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Male and female	2,355,464	0	22	28	11	57	34	43	74	287	2,665	15,460	58,839	146,352	271,956	363,636	418,694	438,593	364,629	274,085

(Continued on the following page)

Table 1. Complete prevalence counts by age, gender, and site at January 1, 2008 (invasive/1st primary cases only, $n = 11.9$ M survivors; ref. 7) (Cont'd)

	All ages	0	01-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		
Female																						
Stomach																						
Male and female	66,010	0	0	4	17	96	120	341	887	1,546	2,857	4,196	5,896	6,791	7,539	8,758	8,975	9,157	8,831	*		
Male	37,739	0	0	0	5	34	42	175	434	724	1,695	2,541	3,474	4,265	5,096	5,352	5,181	5,052	3,670			
Female	28,271	0	0	4	11	62	78	165	453	822	1,163	1,655	2,422	2,526	2,443	3,406	3,793	4,105	5,161	*		
Testis																						
Male and female	200,887	0	126	192	245	988	4,780	9,787	14,214	21,133	27,744	32,005	28,876	22,482	15,667	9,765	6,394	3,670	2,099	720	*	
Male	458,403	0	11	44	174	1,696	4,081	10,666	18,540	31,173	41,644	55,655	59,686	58,063	51,387	40,387	31,847	23,096	17,598	12,658		
Female	100,952	0	0	33	55	409	584	1,588	2,657	5,259	8,275	10,109	12,528	13,615	13,215	10,348	8,735	6,154	4,462	2,925		
Female	357,451	0	11	11	118	1,286	3,497	9,078	15,883	25,914	33,369	45,546	47,158	44,448	38,173	30,039	23,112	16,941	13,136	9,733		
Urinary bladder																						
Male and female	537,428	11	22	33	39	124	276	631	1,105	2,355	5,147	11,333	20,682	33,692	53,001	67,044	79,614	90,369	87,191	84,758		
Male	398,329	0	11	11	39	80	231	441	755	1,641	3,637	8,462	15,684	25,737	40,704	50,961	60,374	67,908	63,990	57,663		
Female	139,099	11	11	22	0	44	145	190	350	713	1,510	2,871	4,998	7,955	12,297	16,083	19,240	22,461	23,202	27,095		

* = not applicable.




Figure 4. Estimated number of persons alive in the U.S. diagnosed with cancer on January 1, 2008 by current age (invasive/1st primary cases only, $n = 11.9$ M survivors; ref. 23).

and older by 2020. These numbers represent a 42% increase in the number of older adult survivors in a relatively brief historical timeframe (2010–2020). As discussed in the introduction, the years 2030 to 2050 are expected to witness the most marked increase in the number of cancer survivors aged 65 and older in U.S. history. The potential magnitude of the impact of the rapidly growing population of older adult cancer survivors on health care delivery systems, and the associated cost of their care, is sobering (8, 14).

Finally, with length of survival increasing, not only can we expect to see older adults living longer with a cancer history but also we will see younger adults aging with such a history. Figure 6 shows the number of survivors aged 65 and older in different phases of care: initial (the first year after diagnosis), the last year of life, and continuing (the care phase in between; refs. 8, 14). The largest increase in the 65 and older survivor population will be for




Figure 5. Estimated number of persons with a history of cancer from 1971 to 2008, by age group, projected through the year 2020 (3, 7).




Figure 6. Population projections of survivors age 65 and older by the 3 phases of care: initial (within 1 year of diagnosis date); last year of life, and continuing phase (between initial and last year of life; refs. 3, 7).

those in the continuing phase of care, the period commonly referred to as the survivorship period.

Discussion

Overall prevalence rates among cancer survivors continue to rise. Forty years after the passage of the National Cancer Act, we have witnessed a 4-fold increase in the number of U.S. cancer survivors from 3 million to close to 12 million. Advances in the treatment and early detection of cancer, in concert with increased life expectancy and a growing aged population are contributing to the rising number of cancer survivors in the United States. The projections reported here represent the most recent data on cancer prevalence and aging and provide projections of the number of older adult cancer survivors through the year 2020. The findings suggest the coming decades will witness a significant increase in the number of those aged 65 and older living long term with a cancer history. By the year 2020, an estimated 11 million survivors will be older adults, representing a 42% increase in their numbers in just 1 decade (2010–2020). Moreover, as shown in Figure 6, the majority of these individuals will be in the survivorship phase following treatment, disease-free or managing chronic conditions, both of which require surveillance and delivery of follow-up care. These trends have important implications for research and planning for future health care needs.

Older adults are an overlooked, understudied, underserved, and vulnerable group of cancer survivors. In an internal 2009 portfolio analysis of NIH-funded grants addressing survivorship outcomes, fewer than 10% of identified studies focused exclusively on the health and well-being of individuals aged 65 and older. Although the number of grants focused on the health and well-being of older adult survivors has been rising slowly, it remains low relative to the number of studies conducted among younger survivor populations. Prospective epidemiologic

studies of older adult survivor populations are urgently needed. We need to know if older adults' posttreatment health profiles and patterns of persistent and long-term cancer-related effects differ markedly from those of younger survivors or older adults' peers unaffected by cancer. How do the presence and progression of preexisting comorbid conditions and age-related health declines interact with the chronic and late effects of cancer? Do interventions addressing the chronic and late effects of cancer developed with younger survivors work for older adult survivors? Prospective data collection and systematic surveillance of cancer care delivery patterns in older adult cancer survivors are also needed. Is the follow-up care received by older survivors different than that for younger survivors and what are the ramifications of this on patterns of morbidity and mortality? These data should include population-based studies, case-control studies, and intervention trials, and should represent research conducted at both NCI-designated comprehensive cancer care settings and community-based settings (27). Within studies of cancer survivors, population-based data (such as that collected by cancer registries) should consider inclusion of comorbidity as a standard data element (20). More cancer clinical trials are needed that include adults age 65 and older, many of whom may have preexisting health conditions and functional limitations, and are often excluded from cancer-related research studies and therapeutic trials specifically (28). These will require trial designs that include and thoughtfully consider the effects of concurrent health conditions, rather than exclude them (29, 30). Clinical trials specifically tailored to older adults are also needed to identify which older adults are at greatest risk for declines in health and psychosocial well-being, to assess treatment tolerance, and to develop and test rehabilitation interventions to help older adults regain functionality after cancer treatment (27).

From a conceptual standpoint, future research on older adults cancer survivors should seek to (i) include psychosocial, behavioral, physiologic, and health services outcomes; (ii) span the survivorship continuum (from primary to quaternary prevention; ref. 31); (iii) differentiate age, period, and cohort effects (23); and (iv) explicitly attend to the heterogeneity and diversity of the older adult cancer survivor population. Older adults are a diverse population across physical, social, psychologic, economic, and cultural dimensions (32, 33). Further, the expectations of the Baby Boomer generation of older adults for "adequate functional status" may be drastically different from the expectations of previous generations. Given this heterogeneity, assessment of functional status, cognitive status, lifestyle behaviors, health-related quality of life, and social support is likely to provide more useful markers for cancer-related outcomes, surveillance, and follow-up care needs than chronological age alone. Beyond inclusion of the areas and topics suggested above, it is critical that psychosocial, behavioral, and biomedical knowledge be integrated in future research and translated expeditiously into practice (34, 35).

The data reported in this article have important implications for health services delivery. As reported by Mariotto and colleagues (11), the current costs associated with cancer care are estimated at 157.77 billion 2010 U.S. dollars, with the potential to reach 173 billion U.S. dollars by the year 2020. The aging of our population contributes significantly to these estimates. The interaction of chronic and late effects of cancer with extant or developing comorbid conditions may lead to more complex medical and psychosocial care needs among older cancer survivors. Because older cancer survivors are likely to be receiving care from multiple providers, they may be exposed to additional risks associated with fragmented care provision (36) and polypharmacy (37, 38). Current approaches to improving the quality of care during and after treatment involve the use of treatment summaries and care plans, shared care models for posttreatment health care delivery, cancer navigator models, and electronic health records to promote information exchange (39, 40). To effectively meet the needs of older adults, models for best practice in cancer care will need to address not only the communication and coordination of care on the provider side of the equation, but also on the consumer side. Efforts will be necessary to empower and facilitate older adults' ability to get their needs met in a fragmented system where mastery of a daunting new array of modern electronic tools (electronic health records, personal data chips, internet use, PDA technology) may be critical to successfully navigating the multiple disciplines and specialties of medicine typically accessed by older adults. Provision of high-quality care for older adult survivors may require adoption of new metrics and strategies. These include the use of geriatric assessments of health and quality of life, the development of geriatric cancer rehabilitation programs, and the development of multidisciplinary teams with expertise in older adults' complex and unique needs. Optimally, these teams will include geriatric specialists in social work, psychology (or neuropsychology), nursing, rehabilitation, and oncology, along with geriatricians. Health services delivery systems face stark challenges as the increasing prevalence of older cancer survivors is accompanied by impending workforce shortages in social work, oncology, and geriatrics (41, 42). Shared care and multidisciplinary models offer a means of more efficiently utilizing the skills of these providers.

Strengths and limitations

Among the strengths of this inquiry are its generation of U.S. population-based cancer prevalence rates using an innovative algorithm to impute and estimate U.S.

prevalence counts and proportions from the most established and highest quality SEER-9 registries, representing approximately 10% of the U.S. population. The findings in this report are subject to a few limitations. First, we projected race- and age-specific proportions from SEER to the U.S. population. Compared with the U.S. population, the SEER population is more urban and has more people who are foreign-born and/or of lower socioeconomic status (1), which limits the generalizability of these findings. Second, persons with multiple primary tumors were categorized according to their first tumor; so the number of survivors by specific cancer sites may be underestimated (24). Third, prevalence is projected under the assumptions of current levels of incidence and survival and dynamic projections of age and size of the U.S. population. These projections can be interpreted as the effect of the growth and aging of the U.S. population, under current cancer control technologies. There is no question that if screening and treatment improve, the number of survivors living long term will increase. However, the aging of the U.S. population makes the greatest contribution to increasing cancer prevalence. Fourth, we were unable to specify whether a survivor was cured, in active therapy, living with a chronic illness or disability, or dying from cancer. Finally, what these prevalence figures do not tell us is the health status of those who are survivors at any given point in time. This is an enduring and troublesome limitation of the current SEER resource platform.

Summary

The observed trend of increasing cancer prevalence rates is expected to continue. This trend is compounded by the anticipated growth in the proportion of cancer survivors who are age 65 and older, many of whom may be expected to have concomitant and complex issues associated with aging. If we are to successfully reduce the burden of cancer in the United States, a concerted effort is needed to better describe this growing population, to define and refine standards of quality care for older adults with cancer, and to develop delivery systems that reflect the multifaceted needs of this diverse and vulnerable population.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Received July 28, 2011; revised August 18, 2011; accepted August 18, 2011; published online October 6, 2011.

References

1. National Cancer Institute. SEER: Surveillance, Epidemiology and End Results Program 2005. [cited 2010 June 7]. Available from: http://seer.cancer.gov/about/SEER_brochure.pdf.
2. Clegg LX, Gail MH, Feuer EJ. Estimating the variance of disease-prevalence estimates from population-based registries. *Biometrics* 2002;58:684-8.

3. Gigli A, Mariotto A, Clegg LX, Tavilla A, Corazziari I, Capocaccia R, et al. Estimating the variance of cancer prevalence from population-based registries. *Stat Methods Med Res* 2006;15:235–53.
4. Mariotto AB, Rowland JH, Yabroff KR, Scoppa S, Hachey M, Ries L, et al. Long-term survivors of childhood cancers in the United States. *Cancer Epidemiol Biomarkers Prev* 2009;18:1033–40.
5. Simonetti A, Gigli A, Capocaccia R, Mariotto A. Estimating complete prevalence of cancers diagnosed in childhood. *Stat Med* 2008;27:990–1007.
6. Mariotto A, Gigli A, Capocaccia R, Tavilla A, Clegg LX, Depuy M, et al. Complete and limited duration cancer prevalence estimates. In: Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, Edwards BK, editors. *SEER cancer statistics review, 1973–1999*. Bethesda, MD: National Cancer Institute; 2002.
7. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. *SEER cancer statistics review, 1975–2008*. Bethesda, MD: National Cancer Institute; 2011.
8. National Cancer Institute. *SEER cancer statistics, 1975–2008 2011*. [cited 2011 July 1]. Available from: <http://seer.cancer.gov>.
9. Centers for Disease Control and Prevention. *Healthy aging: helping people to live long and productive lives and enjoy a good quality of life. At a glance 2011*. [cited]. Available from: <http://www.cdc.gov/chronicdisease/resources/publications/aag/aging.htm>
10. Administration on Aging. *A profile of older Americans aged 65+*. Washington, DC: U.S. Department of Health and Human Services; 2009.
11. Federal Interagency Forum on Aging-related Statistics. *Older Americans update 2010: Key indicators of well-being*. Washington, DC: U.S. Government Printing Office; 2010.
12. Bellizzi KM, Rowland JH. Role of comorbidity, symptoms and age in the health of older survivors following treatment for cancer. *Aging Health* 2007;3:625–35.
13. Costanzo ES, Ryff CD, Singer BH. Psychosocial adjustment among cancer survivors: findings from a national survey of health and well-being. *Health Psychol* 2009;28:147–56.
14. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. *J Natl Cancer Inst* 2011;103:117–28.
15. Centers for Disease Control and Prevention & The Merck Company Foundation. *The state of aging and health in America 2007*. Whitehouse Station, NJ: The Merck Company Foundation; 2007.
16. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. *JAMA* 2001;285:885–92.
17. Extermann M. Interaction between comorbidity and cancer. *Cancer Control* 2007;14:13–22.
18. Greenfield S, Blanco DM, Elashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. *JAMA* 1987;257:2766–70.
19. Ballard-Barbash R, Potosky AL, Harlan LC, Nayfield SG, Kessler LG. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. *J Natl Cancer Inst* 1996;88:716–26.
20. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. *JAMA* 2004;291:2441–7.
21. Given CW, Given B, Azzouz F, Stommel M, Kozachik S. Comparison of changes in physical functioning of elderly patients with new diagnoses of cancer. *Med Care* 2000;38:482–93.
22. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. *J Gerontol A Biol Sci Med Sci* 2003;58:82–91.
23. Trask PC, Blank TO, Jacobsen PB. Future perspectives on the treatment issues associated with cancer and aging. *Cancer* 2008;113:3512–8.
24. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. *Cancer Epidemiol Biomarkers Prev* 2007;16:566–71.
25. National Cancer Institute. *Cancer prevalence statistics: approaches to estimation using cancer registry data*. 2010 [cited 2011 July 1]. Available from: <http://srab.cancer.gov/prevalence/approaches.html>.
26. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. *SEER cancer statistics review, 1975–2008*. [cited 2011 July 1, based on November 2010 SEER data submission, posted to the SEER web site]. Available from: http://seer.cancer.gov/csr/1975_2007/.
27. National Institute on Aging, National Cancer Institute. *Exploring the role of cancer centers for integrating aging and cancer research*. Bethesda, MD: National Institutes of Health; 2001.
28. Payne JK, Hendrix CC. Clinical trial recruitment challenges with older adults with cancer. *Appl Nurs Res* 2010;23:233–7.
29. Avis NE, Deimling GT. Cancer survivorship and aging. *Cancer* 2008;113:3519–29.
30. Hurria A, Cohen HJ, Extermann M. Geriatric oncology research in the cooperative groups: a Report of a SIOG Special Meeting. *J Geriatr Oncol* 2010;1:40–4.
31. Bellizzi KM, Mustian KM, Paless OG, Diefenbach M. Cancer survivorship and aging: moving the science forward. *Cancer* 2008;113:3530–9.
32. Given B, Given CW. Older adults and cancer treatment. *Cancer* 2008;113:3505–11.
33. Rowland JH, Bellizzi KM. Cancer survivors and survivorship research: a reflection on today's successes and tomorrow's challenges. *Hematol Oncol Clin North Am* 2008;22:181–200, v.
34. Institute of Medicine. *Cancer care for the whole patient: Meeting psychosocial health needs*. Washington, DC: The National Academies Press; 2008.
35. Institute of Medicine. *Retooling for an aging America*. Washington, DC: The National Academies Press; 2008.
36. Institute of Medicine. *Crossing the quality chasm: a new health system for the 21st century*. Washington, DC: The National Academies Press; 2001.
37. Lacasse C. Polypharmacy and symptom management in older adults. *Clin J Oncol Nurs* 2011;15:27–30.
38. Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. *Lancet Oncol* 2011. [Epub ahead of print].
39. Institute of Medicine. *From cancer patient to cancer survivor: lost in transition*. Washington, DC: The National Academies Press; 2006.
40. Coleman EA. Falling through the cracks: challenges and opportunities for improving transitional care for persons with continuous complex care needs. *J Am Geriatr Soc* 2003;51:549–55.
41. Erikson C, Salsberg E, Forte G, Bruinooge S, Goldstein M. Future supply and demand for oncologists: challenges to assuring access to oncology services. *J Oncol Pract* 2007;3:79–86.
42. Messner C. Impending oncology social worker shortage? *Oncology Issues* 2010;September/October:46–7.